Table 5.
Fully adjusted model for cardiac endpoints according to clinical characteristics and levels of biomarkers
| CV death |
MI |
HF |
CV death/HF |
|||||
|---|---|---|---|---|---|---|---|---|
| HRadj; 95% CI | P-value | HRadj; 95% CI | P-value | HRadj; 95% CI | P-value | HRadj; 95% CI | P-value | |
| cTnI Ultra >0.04 ng/mL | 1.88; 1.25–2.83 | 0.002 | 2.97; 2.12–4.06 | <0.001 | 2.41; 1.47–3.96 | <0.001 | 1.93; 1.38–2.71 | <0.001 |
| NT-ProBNP >400 pg/mL | 2.37; 1.64–3.41 | <0.001 | 1.07; 0.83–1.38 | 0.58 | 3.36; 2.22–5.10 | <0.001 | 2.73; 2.02–3.68 | <0.001 |
| hs-C-reactive protein >15 mg/L | 1.06; 0.78–1.46 | 0.70 | 1.01; 0.79–1.32 | 0.93 | 1.39; 1.01–1.91 | 0.045 | 1.15; 0.90–1.49 | 0.27 |
| MPO >670 pmol/L | 1.28; 0.96–1.71 | 0.088 | 0.94; 0.75–1.17 | 0.57 | 1.55; 1.14–2.11 | 0.005 | 1.26; 1.00–1.59 | 0.052 |
Hazard ratio adjusted for TIMI risk score, creatinine clearance <60 mL/min, and prior heart failure, MPO >670 pmol/L, NT-proBNP >400 pg/mL, cTnI ≥0.04 ng/mL, and hs-C-reactive protein >15 mg/L.